Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

作者: M T Huizing , G Giaccone , L J van Warmerdam , H Rosing , P J Bakker

DOI: 10.1200/JCO.1997.15.1.317

关键词:

摘要: PURPOSETo investigate the pharmacokinetics and pharmacodynamics of paclitaxel (P) carboplatin (C) in a sequence-finding dose-escalating study untreated non-small-cell lung cancer (NSCLC) patients.PATIENTS AND METHODSFifty-five chemotherapy-naive patients with NSCLC were entered onto pharmacokinetic part large phase I trial which P was administered as 3-hour infusion at dosages 100 to 250 mg/m2, C over 30 minutes 300 400 mg/m2. Patients randomized for sequence administration, first followed by or vice versa. Each patient received alternate during second subsequent courses.RESULTSThe most important hematologic toxicity encountered-was neutropenia. Hematologic not dependent on administered, but there cumulative Nonhematologic toxicities consisted mainly vomiting, myalgia, arthralgia. No sequence-dependent interactions area unde...

参考文章(29)
L. J. C. van Warmerdam, M. T. Huizing, G. Giaccone, P. J. M. Bakker, J. B. Vermorken, P. E. Postmus, N. van Zandwijk, M. G. J. Koolen, W. W. ten Bokkel Huinink, R. A. A. Maes, W. J. F. van der Vijgh, C. H. N. Veenhof, J. H. Beijnen, Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Non-Small Cell Lung Cancer: A European Cancer Centre (ECC) Study Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. pp. 67- 82 ,(1996) , 10.1007/978-1-4899-0218-4_7
J E Liebmann, D Teague, J Fisher, J A Cook, Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncology Research. ,vol. 6, pp. 25- 31 ,(1994)
M D Dabholkar, R J Parker, K B Lee, E Reed, F Bostick-Bruton, Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Journal of The National Cancer Institute Monographs. pp. 83- 88 ,(1993)
E K Rowinsky, M R Gilbert, W P McGuire, D A Noe, L B Grochow, A A Forastiere, D S Ettinger, B G Lubejko, B Clark, S E Sartorius, Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study Journal of Clinical Oncology. ,vol. 9, pp. 1692- 1703 ,(1991) , 10.1200/JCO.1991.9.9.1692
P A Francis, J R Rigas, M G Kris, K M Pisters, J P Orazem, K J Woolley, R T Heelan, Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 12, pp. 1232- 1237 ,(1994) , 10.1200/JCO.1994.12.6.1232
L Gianni, C M Kearns, A Giani, G Capri, L Viganó, A Lacatelli, G Bonadonna, M J Egorin, Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. Journal of Clinical Oncology. ,vol. 13, pp. 180- 190 ,(1995) , 10.1200/JCO.1995.13.1.180
T. Walle, G. N. Kumar, U. K. Walle, Kapil Bhalla, Taxol metabolism and disposition in cancer patients. Drug Metabolism and Disposition. ,vol. 23, pp. 506- 512 ,(1995)
C J Langer, J C Leighton, R L Comis, P J O'Dwyer, C A McAleer, C A Bonjo, P F Engstrom, S Litwin, R F Ozols, Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. Journal of Clinical Oncology. ,vol. 13, pp. 1860- 1870 ,(1995) , 10.1200/JCO.1995.13.8.1860
E A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, L Gianni, J Myles, M E van der Burg, I Kerr, J B Vermorken, K Buser, N Colombo, European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology. ,vol. 12, pp. 2654- 2666 ,(1994) , 10.1200/JCO.1994.12.12.2654